SEC Form 4 · accession 0001209191-15-067793
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Patrick Soon-Shiong
Officer — Chairman and CEO · Director · 10% Owner
MP 13 Ventures, LLC
10% Owner
Cambridge Equities, LP
10% Owner
Period of report
Aug 21, 2015
Accepted (ET)
Aug 25, 2015 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 21, 2015 | P | 450,000 | $23.00 | A | 41,016,557 | I | See footnote |
| Common StockF2 | holding | — | — | — | 600,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares held by Cambridge Equities, LP ("Cambridge Equities"). MP 13 Ventures, LLC ("MP 13 Ventures") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities.
- F2Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock. Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the RSUs will vest as follows: 50% of the RSUs vested on the July 27, 2015, and 50% of the RSUs will vest on July 27, 2016.